Time for testing incretin therapies in early type 1 diabetes?

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 6, 2010, Pages 2607-2609

  Bosi, Emanuele ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; INCRETIN; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; PEPTIDE; VENOM;

AUTOIMMUNE DISEASE; EARLY DIAGNOSIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NONHUMAN; NOTE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; DIABETES MELLITUS, TYPE 1; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN-SECRETING CELLS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; PEPTIDES; VENOMS;

EID: 77954515294     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2741     Document Type: Note

References (13)

1. Lovshin JA, Drucker DJ 2009 Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262-269
2. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
3. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC 2007 Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibodies by enhancing recovery of β-cells. Endocrinology 148:5136-5144
4. Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ 2008 Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149:1338-1349
5. Kim SJ, Nian C, Doudet DJ, McIntosh CH 2009 Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 58:641-651
6. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC 2005 Sustained β-cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 48:2221-2228
7. Nielsen LR, Rehfeld JF, Pedersen-Bjergaard U, Damm P, Mathiesen ER 2009 Pregnancy-induced rise in serum C-peptide concentrations in women with type 1 diabetes. Diabetes Care 32:1052-1057
8. Gangemi A, Salehi P, Hatipoglu B, Martellotto J, Barbaro B, Kuechle JB, Qi M, Wang Y, Pallan P, Owens C, Bui J, West D, Kaplan B, Benedetti E, Oberholzer J 2008 Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant 8:1250-1261
9. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ 2009 One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32:762-768
10. Rother KI, Spain LM, Wesley RA, Digon BJ 3rd, Baron A, Chen K, Nelson P, Dosch HM, Palmer JP, Brooks-Worrell B, Ring M, Harlan DM 2009 Effects of exenatide alone and in combination with daclizumab on β-cell function in long-standing type 1 diabetes. Diabetes Care 32:2251-2257
11. Steffes MW, Sibley S, Jackson M, Thomas W 2003 β-Cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26:832-836 (Pubitemid 36929351)
12. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S 2007 Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50:1148-1155
13. Blandino-Rosano M, Perez-Arana G, Mellado-Gil JM, Segundo C, Aguilar-Diosdado M 2008 Anti-proliferative effect of pro-inflammatory cytokines in cultured β-cells is associated with extracellular signal-regulated kinase 1/2 pathway inhibition: protective role of glucagon-like peptide-1. J Mol Endocrinol 41:35-44